KBC Group’s Vir Biotechnology VIR Stock Holding History

KBC Group’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-5,958	Closed	-$39K	–	1816
2025 Q1	$39K	Sell	5,958 -3,012	-34%	-$26.8K	﹤0.01%	1833
2024 Q4	$66K	Buy	8,970 +5,177	+136%	+$40.8K	﹤0.01%	1759
2024 Q3	$28K	Hold	3,793	–	–	﹤0.01%	1832
2024 Q2	$34K	Buy	3,793 +1,274	+51%	+$12.2K	﹤0.01%	1794
2024 Q1	$26K	Hold	2,519	–	–	﹤0.01%	1801
2023 Q4	$25K	Hold	2,519	–	–	﹤0.01%	1845
2023 Q3	$24K	Sell	2,519 -2,980	-54%	-$42.5K	﹤0.01%	1857
2023 Q2	$135K	Sell	5,499 -587	-10%	-$14.7K	﹤0.01%	1076
2023 Q1	$142K	Sell	6,086 -617	-9%	-$15.8K	﹤0.01%	1084
2022 Q4	$170K	Hold	6,703	–	–	﹤0.01%	1022
2022 Q3	$129K	Hold	6,703	–	–	﹤0.01%	1093
2022 Q2	$171K	Buy	+6,703	New	+$156K	﹤0.01%	1032

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

KBC Group's VIR Position: Q2 2025 in Review

KBC Group sold out of Vir Biotechnology (VIR) in Q2 2025, closing a stake of 5,958 shares — an estimated $39K sold.

KBC Group first reported a position in VIR in Q2 2022 and held it in 12 quarters. The position peaked at $171K in Q2 2022. 213 funds tracked by Wall St. Rank hold VIR as of Q2 2025.

KBC Group reported no remaining Vir Biotechnology position as of Q2 2025 after selling out during the quarter.
KBC Group sold 5,958 Vir Biotechnology shares in Q2 2025, an estimated $39K.
KBC Group first reported a position in Vir Biotechnology in Q2 2022 and held it in 12 quarters.
KBC Group's Vir Biotechnology position peaked at $171K in Q2 2022.
213 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2025.

Based on KBC Group's 13F filing for Q2 2025, filed 8 Aug 2025.